Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Hemophagocytic Lymphohistiocytosis Channel

Explore the latest updates and expert interviews

Explore The Hemophagocytic Lymphohistiocytosis Channel

Hemophagocytic lymphohistiocytosis is a rare inherited immune disorder characterized by the activation of cytotoxic T-cells and is usually present in infants.

Learn more about treatment approaches with The Hemophagocytic Lymphohistiocytosis Channel, featuring key updates in the use of immune suppressants, allogeneic hematopoietic stem cell transplantation, and novel immunotherapeutics.

Early activity of ELA026, a pan-SIRP antibody, in patients with T-cell lymphoma 1:43
Early activity of ELA026, a pan-SIRP antibody, in patients with T-cell lymphoma
Swaminathan Iyer • 20 Jun 2025
A Phase I trial of ELA026, a SIRP inhibitor, in treatment-naïve HLH 1:45
A Phase I trial of ELA026, a SIRP inhibitor, in treatment-naïve HLH
Swaminathan Iyer • 9 Dec 2024
Evaluating the suitability of sHLH diagnostic criteria in adults 0:56
Evaluating the suitability of sHLH diagnostic criteria in adults
Catherine Broome • 12 Dec 2022
Emapalumab for pediatric pHLH: pivotal study results 11:43
Emapalumab for pediatric pHLH: pivotal study results
Franco Locatelli • 4 Dec 2018

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals